fluoxetine has been researched along with Autoimmune Diabetes in 8 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous work has demonstrated that chronic administration of the serotonin reuptake inhibitor (SSRI) fluoxetine augments counterregulatory responses to hypoglycemia in healthy humans." | 9.13 | Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. ( Briscoe, VJ; Davis, SN; Ertl, AC; Tate, DB, 2008) |
| "Reduction in depression symptoms was significantly greater in patients treated with fluoxetine compared with those receiving placebo (BDI, -14." | 9.09 | Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. ( Clouse, RE; Freedland, KE; Griffith, LS; Lustman, PJ, 2000) |
| "A 17-year-old boy with type 1 diabetes mellitus developed new loss of hypoglycemia awareness while being treated with fluoxetine hydrochloride for depression." | 7.70 | Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride. ( Burgart, V; Sawka, AM; Zimmerman, D, 2000) |
| "Previous work has demonstrated that chronic administration of the serotonin reuptake inhibitor (SSRI) fluoxetine augments counterregulatory responses to hypoglycemia in healthy humans." | 5.13 | Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. ( Briscoe, VJ; Davis, SN; Ertl, AC; Tate, DB, 2008) |
| "Reduction in depression symptoms was significantly greater in patients treated with fluoxetine compared with those receiving placebo (BDI, -14." | 5.09 | Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. ( Clouse, RE; Freedland, KE; Griffith, LS; Lustman, PJ, 2000) |
| "A 17-year-old boy with type 1 diabetes mellitus developed new loss of hypoglycemia awareness while being treated with fluoxetine hydrochloride for depression." | 3.70 | Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride. ( Burgart, V; Sawka, AM; Zimmerman, D, 2000) |
| "Fluoxetine treatment significantly reduced the BW gain, hyperglycaemia, creatinine, and BUN in diabetic rats." | 1.72 | Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes. ( Alarcón-Torrecillas, C; Fernández-González, JF; García-Domingo, M; García-Pedraza, JÁ; López, C; Martín, ML; Morán, A; Rodríguez-Barbero, A, 2022) |
| " Median effective dose was interpolated from the triplicated experiments and the dose-response curves were generated for each drug-virus combination." | 1.56 | A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses. ( Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Pedraza, JÁ | 1 |
| Fernández-González, JF | 1 |
| López, C | 1 |
| Martín, ML | 1 |
| Alarcón-Torrecillas, C | 1 |
| Rodríguez-Barbero, A | 1 |
| Morán, A | 1 |
| García-Domingo, M | 1 |
| Sioofy-Khojine, AB | 1 |
| Honkimaa, A | 1 |
| Hyöty, H | 1 |
| Briscoe, VJ | 1 |
| Ertl, AC | 1 |
| Tate, DB | 1 |
| Davis, SN | 1 |
| Bech, P | 1 |
| Raabaek Olsen, L | 1 |
| Jarløv, N | 1 |
| Hammer, M | 1 |
| Schütze, T | 1 |
| Breum, L | 1 |
| Sawka, AM | 1 |
| Burgart, V | 1 |
| Zimmerman, D | 1 |
| Lustman, PJ | 1 |
| Freedland, KE | 1 |
| Griffith, LS | 1 |
| Clouse, RE | 1 |
| Lear, J | 1 |
| Burden, AC | 1 |
| Ramirez, LC | 1 |
| Rosenstock, J | 1 |
| Strowig, S | 1 |
| Cercone, S | 1 |
| Raskin, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 6[NCT00592670] | 48 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| Program ACTIVE: Implementing a Cognitive Behavioral Therapy and Physical Activity Program for Black Men With Comorbid Diabetes and Depression[NCT04369001] | 0 participants (Actual) | Interventional | 2020-12-31 | Withdrawn (stopped due to Due to covid-19 and social distancing, this study was terminated.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for fluoxetine and Autoimmune Diabetes
| Article | Year |
|---|---|
Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes.
Topics: Adult; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Fluoxetine; Homeostasis; Humans; Hypo | 2008 |
Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Depression; Diabetes Mellitus, | 2000 |
6 other studies available for fluoxetine and Autoimmune Diabetes
| Article | Year |
|---|---|
Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes.
Topics: Administration, Oral; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2022 |
A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses.
Topics: A549 Cells; Amides; Antiviral Agents; Azithromycin; Benzimidazoles; Coxsackievirus Infections; Diabe | 2020 |
A case of sequential anti-stress medication in a patient with major depression resistant to amine-reuptake inhibitors.
Topics: Amines; Antidepressive Agents; Anxiety Disorders; Dehydroepiandrosterone; Depressive Disorder, Major | 1999 |
Loss of hypoglycemia awareness in an adolescent with type 1 diabetes mellitus during treatment with fluoxetine hydrochloride.
Topics: Adolescent; Awareness; Depression; Diabetes Mellitus, Type 1; Fluoxetine; Humans; Hypoglycemia; Male | 2000 |
Fluoxetine side-effects mimicking hypoglycaemia.
Topics: Adult; Diabetes Mellitus, Type 1; Diagnosis, Differential; Female; Fluoxetine; Humans; Hypoglycemia | 1992 |
Effective treatment of bulimia with fluoxetine, a serotonin reuptake inhibitor, in a patient with type I diabetes mellitus.
Topics: Adult; Bulimia; Diabetes Mellitus, Type 1; Female; Fluoxetine; Humans; Neurotransmitter Uptake Inhib | 1990 |